Maze Therapeutics, Inc. (NASDAQ: MAZE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 13.77% | Shs Outstand | 55.35M | Perf Week | -8.46% |
| Market Cap | 1.25B | Forward P/E | - | EPS next Y | -3.21 | Insider Trans | -4.79% | Shs Float | 15.98M | Perf Month | -24.30% |
| Enterprise Value | 1.10B | PEG | 0.16 | EPS next Q | -0.79 | Inst Own | 120.25% | Short Float | 10.69% | Perf Quarter | -12.31% |
| Income | -125.39M | P/S | 62.32 | EPS this Y | - | Inst Trans | - | Short Ratio | 10.79 | Perf Half Y | -54.44% |
| Sales | 20.00M | P/B | 2.93 | EPS next Y | -16.18% | ROA | -25.13% | Short Interest | 5.92M | Perf YTD | -45.64% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -34.94% | 52W High | 53.64 -58.02% | Perf Year | -4.17% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -28.35% | 52W Low | 22.01 2.32% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 95.28% | Volatility | 5.20% 4.86% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 55.21 | EPS Y/Y TTM | -3339.07% | Oper. Margin | -728.06% | ATR (14) | 1.39 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 18.31 | Sales Y/Y TTM | - | Profit Margin | -667.95% | RSI (14) | 25.91 | Recom | 1.86 |
| Dividend Gr. 3/5Y | - | Current Ratio | 18.31 | EPS Q/Q | 1.30% | SMA20 | -14.39% | Beta | 0.80 | Target Price | 64.00 |
| Payout | 0.00% | Debt/Eq | 0.13 | Sales Q/Q | - | SMA50 | -17.99% | Rel Volume | 2.72 | Prev Close | 23.44 |
| Employees | 141 | LT Debt/Eq | 0.05 | Earnings | Nov 05 | SMA200 | -33.12% | Avg Volume | 549.35K | Price | 22.52 |
| IPO Date | Jan 31, 2025 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -5.95% 88.24% | Net Debt/EBITDA | 1.09 | Volume | 1,494,816 | Change | -3.92% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Apr-14-26 | Reiterated | Truist Securities | Buy | $68 → $64 |
| Mar-17-26 | Reiterated | Truist Financial | $68 | |
| Mar-10-26 | Initiated | Mizuho | Outperform | |
| Jan-16-26 | Reiterated | BTIG | Buy | $30 → $46 |
| Dec-19-25 | Reiterated | Guggenheim | Buy | $34 → $46 |
| Dec-04-25 | Initiated | Wells Fargo | Overweight | $55 |
| Dec-03-25 | Reiterated | HC Wainwright & Co. | Buy | $60 |
| Nov-13-25 | Initiated | Raymond James | Strong Buy | $48 |
| Sep-15-25 | Reiterated | Guggenheim | Buy | $34 |
| Sep-02-25 | Initiated | BTIG | Buy | $30 |
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | |
|---|---|---|---|---|---|
| Total Revenue | 0 | 168 | 0 | — | |
| Cost of Goods Sold Incl. D&A | 2 | 0 | 0 | — | |
| Gross Profit | -2 | 168 | 0 | — | |
| Selling, General and Administrative Excl. Other | 34 | 26 | 25 | — | |
| Research and Development | 108 | 83 | 74 | — | |
| Other Operating Expense | -2 | 1 | 0 | — | |
| Operating Income | -143 | 58 | -99 | — | |
| Interest Expense | 0 | 0 | 0 | — | |
| Unusual Expense | — | — | — | — | |
| Non-Operating Income (Expense) | 12 | -4 | -2 | — | |
| Net Income Before Taxes | -131 | 53 | -100 | — | |
| Income Taxes | 0 | 1 | 0 | — | |
| Consolidated Net Income | -131 | 52 | -100 | — | |
| Net Income From Continuing Operations | -131 | 52 | -100 | — | |
| Net Income | -131 | 52 | -100 | — | |
| EPS (Recurring) | -3.05 | 0.08 | -2.29 | — | |
| EPS (Basic, Before Extraordinaries) | -3.05 | 0.08 | -2.29 | — | |
| EPS (Diluted) | -3.05 | 0.08 | -2.29 | — | |
| EBITDA | -129 | 57 | -96 | — | |
| Other After Tax Adjustments | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | |
| Gross Margin | — | 100.00 | — | — | |
| Operating Margin | — | 34.52 | — | — | |
| Net Margin | — | 30.95 | — | — | |
| Shares Outstanding | 43 | 44 | 44 | — | |
| Market Capitalization | 1,781 | — | — | — | |
| Operating Lease Expense | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Bernstein Harold | President, R&D & CMO | Sep 04 '26 | Sale | 26.22 | 9,705 | 254,502 | 0 | Sep 08 |
| Courtney Phillips | GC and Corp. Secretary | Sep 03 '26 | Sale | 26.01 | 2,012 | 52,333 | 7,007 | Sep 04 |
| Bernstein Harold | President, R&D & CMO | Sep 03 '26 | Sale | 26.01 | 5,189 | 134,969 | 9,705 | Sep 04 |
| Dandekar Atul | CSBO | Sep 03 '26 | Sale | 26.01 | 3,243 | 84,354 | 32,316 | Sep 04 |
| Coloma Jason V | Chief Executive Officer | Sep 03 '26 | Sale | 26.01 | 11,411 | 296,807 | 27,362 | Sep 04 |
| Coloma Jason V | Chief Executive Officer | Sep 02 '26 | Sale | 26.47 | 11,227 | 297,148 | 38,773 | Sep 04 |
| Bernstein Harold | President, R&D & CMO | Sep 02 '26 | Sale | 26.47 | 5,106 | 135,142 | 14,894 | Sep 04 |
| Courtney Phillips | GC and Corp. Secretary | Sep 02 '26 | Sale | 26.47 | 1,981 | 52,431 | 9,019 | Sep 04 |
| Dandekar Atul | CSBO | Sep 02 '26 | Sale | 26.47 | 3,191 | 84,457 | 35,559 | Sep 04 |
| Dandekar Atul | CSBO | Sep 01 '26 | Option Exercise | 0.00 | 12,500 | 0 | 38,750 | Sep 03 |
| Courtney Phillips | GC and Corp. Secretary | Sep 01 '26 | Option Exercise | 0.00 | 11,000 | 0 | 11,000 | Sep 03 |
| Coloma Jason V | Chief Executive Officer | Sep 01 '26 | Sale | 26.29 | 34,501 | 906,999 | 18,151 | Sep 03 |
| Coloma Jason V | Chief Executive Officer | Sep 01 '26 | Option Exercise | 0.00 | 50,000 | 0 | 50,000 | Sep 03 |
| Bernstein Harold | President, R&D & CMO | Sep 01 '26 | Option Exercise | 4.65 | 36,141 | 168,189 | 20,000 | Sep 03 |
| Bernstein Harold | President, R&D & CMO | Sep 01 '26 | Sale | 26.36 | 16,141 | 425,512 | 0 | Sep 03 |